Key points from article :
João Pedro de Magalhães outlined some of the great strides made in the biology of aging.
The number of compounds to increase longevity is growing exponentially.
It was 300 in 2005, 1300 in 2015, and 2000 in 2020.
Longevity companies also doubtlessly increased dramatically.
Acquisition of longevity companies by big pharma is beginning to occur.
Seen its first clinical failures, a notable rite of passage for all new fields of medicine.
List of ongoing clinical trials is growing, including COVID, macular degeneration, frailty, and neurodegenerative diseases.
Future therapies to broadly target longevity in their applications to the FDA.
Interest has been growing in off-label prescriptions and nutritional supplements.
Computer-based methods being applied to the field of longevity.
May eventually play a role in personalized, precision medicine.
While the future is unknown, Dr. Magalhães gives us plenty of reasons for optimism.
Feature article published in Drug Discovery Today.
